HealthBIO 2026

Pixelgen Technologies has closed an oversubscribed USD 15.5 million Series B financing to accelerate global commercialization of its Proxiome Kit and expand the company’s presence in key markets.

Merck and Moderna have reported positive topline results from the Phase 3 INTerpath-001 trial of intismeran autogene in combination with Keytruda in patients with completely resected, high-risk melanoma.

The company reported a 16% increase in revenue at constant exchange rates in the first six months of 2026, driven mainly by continued growth in Vyepti and Rexulti.

SynAct Pharma has signed a term sheet with Brazilian pharmaceutical company Hipolabor to co-develop and commercialize resomelagon for dengue and other viral infections in Brazil.

The company has received regulatory approval from the European Medicines Agency, to conduct PP-CT04, a two-part, randomized, double-blind, placebo-controlled, parallel-group, 12‑week trial investigating the safety, tolerability, pharmacokinetics and efficacy of XEN-D0501 in obese participants.

BioArctic and Mesenkia Therapeutics have signed a research collaboration agreement to explore a novel antibody-based approach for glioblastoma, one of the most aggressive and treatment-resistant forms of brain cancer, where effective delivery of large molecules to the brain remains a major challenge.

The Lundbeck Foundation has awarded DKK 78 million to a pan-Nordic centre that will focus on research into the glymphatic system.